Mark Dammert, MD
Otolaryngology · Kyle, TXNPI 1417168345
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Aerin Medical Inc. accounts for 90.6% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $19,884 and has fallen 95.8% since, to $844 in 2025. Among otolaryngology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $328.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerin Medical Inc.$30K
- Inspire Medical Systems, Inc.$448
- Medtronic$420
- Regeneron Healthcare Solutions, Inc.$395
- Sanofi$307
- Acclarent, Inc$293
- plus $1K from 11 others
What the payments were for
- Consulting fees$9,65029%
- Speaking & faculty fees$18,80057%
- Travel & lodging$5292%
- Food & beverage$3,85712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerin Medical Inc. | 34 | $29,757 |
| Inspire Medical Systems, Inc. | 7 | $448 |
| Medtronic | 3 | $420 |
| Regeneron Healthcare Solutions, Inc. | 15 | $395 |
| Sanofi | 9 | $307 |
| Acclarent, Inc | 7 | $293 |
| Olympus America Inc. | 2 | $279 |
| Stryker | 3 | $208 |
| GSK | 5 | $207 |
| Smith+Nephew | 2 | $147 |
| Optinose US, Inc. | 5 | $93 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $87 |
| Intersect ENT, Inc. | 2 | $74 |
| Advanced Bionics, LLC | 2 | $61 |
| AstraZeneca | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Itamar Medical Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVAER STYLUS$26,290
- RHINAER STYLUS$25,090
- VivAer$500
- RhinAer$500
- NIM Vital$159
- Inspire Upper Airway Stimulation System$159
- RHINO-LARYNGO VIDEOSCOPE$141
- ENTELLUS - FIAGON SINUS NAVIGATION SYSTEM$139
- Olympus Capital Accessories$138
- Halo$133
- TULA$133
- Vivaer RF Stylus$129
- Inspire$127
- NUCALA$120
- DUPIXENT$117
- NUVENT$111
How this compares
$32,836 in reported general payments places this provider in the 95th percentile of 729 otolaryngology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 25 | $89,728 |
| Epinephrine | 22 | $3,958 |
| Azelastine Hcl | 78 | $2,076 |
| Ipratropium Bromide | 34 | $842 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $168 |
| Montelukast Sodium | 12 | $163 |
| Fluticasone Propionate | 20 | $140 |
| Mupirocin | 21 | $135 |
| Amitriptyline Hcl | 30 | $109 |
| Doxycycline Hyclate | 12 | $90 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $78 |
| Gabapentin | 13 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAEpinephrine | $19 | $3,95822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 otolaryngology providers in Texas.
Other otolaryngology in Kyle
- Marc DeanFort Worth$486K
- Amber LuongHouston$426K
- Arjuna KuperanHouston$348K
- Ronald KuppersmithCollege Station$325K
- Ron KarniHouston$317K
- Philip ChenSan Antonio$305K
- Jordan RihaniSouthlake$280K
- Keith MathenyFrisco$269K
- Martin CitardiHouston$245K
- James AtkinsSan Antonio$205K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.